# Guselkumab and IL-23 p19 Mechanism

## What is the Guselkumab IL-23 binding p19 mechanism?

I'll pull up the structural and mechanistic literature on guselkumab's binding to the IL-23 p19 subunit.

### Guselkumab's Mechanism of Action
Guselkumab is a fully human IgG1 monoclonal antibody that binds specifically to the p19 subunit of IL-23, blocking its interaction with the IL-23 receptor. Here's how the mechanism works at several levels:

#### p19 epitope binding  
The p19 subunit is unique to IL-23 (unlike p40, which is shared with IL-12), so targeting p19 gives selectivity for IL-23 without affecting IL-12. Hydrogen-deuterium exchange studies characterize guselkumab's epitope on p19 as large — roughly 2,240 Ų of solvent-accessible surface area — and predominantly non-hydrophobic with a net-neutral surface charge. Critically, this epitope location sterically prevents IL-23 from engaging its receptor (IL-23R/IL-12Rβ1 complex), blocking downstream signaling. Binding affinity is in the picomolar range, and the antibody inhibits IL-23-induced STAT3 phosphorylation with an IC50 of approximately 0.2 nM in human PBMCs.

#### Downstream signaling consequences  
When guselkumab blocks IL-23/receptor engagement, the JAK/STAT pathway (primarily JAK2–TYK2 activating STAT3) is not activated in responding lymphoid cells. This blunts the IL-23-driven differentiation and maintenance of Th17 cells, reducing downstream production of IL-17A, IL-17F, IL-22, and TNF — the effector cytokines responsible for tissue inflammation in psoriasis and psoriatic arthritis. Early clinical biopsy data confirmed that guselkumab treatment significantly reduces serum IL-17A and psoriasis gene expression at 12 weeks.

#### A mechanistic wrinkle: CD64-mediated enrichment at the source  
More recent work (2022–2025) has revealed that guselkumab's native IgG1 Fc region allows it to bind CD64 (FcγRI), which is highly expressed on the IL-23-producing myeloid cells (macrophages, monocytes, dendritic cells) concentrated in lesional psoriatic tissue. This gives guselkumab something risankizumab lacks: guselkumab can anchor to CD64+ macrophages via its Fc domain while simultaneously capturing IL-23 secreted from those same cells. The guselkumab-IL-23 complex is then internalized and trafficked to low-pH lysosomal compartments, effectively removing IL-23 from the inflamed microenvironment at its source of production. In co-culture assays where IL-23 was produced endogenously by CD64+ cells rather than added exogenously, guselkumab showed roughly 10-fold greater potency than risankizumab for inhibiting IL-23 signaling — an Fc-dependent effect. CD64 binding does not trigger cytokine release from myeloid cells, so this mechanism appears to be a pure clearance mechanism rather than an activating one.

#### How this compares structurally to other p19 inhibitors  
All three selective p19 blockers (guselkumab, risankizumab, tildrakizumab) bind distinct epitopes on p19, with only a 10-residue overlap region shared among them — and that shared region lies outside the IL-23 receptor-binding interface. Epitope size correlates strongly with binding affinity and clinical efficacy: guselkumab's large epitope surface area tracks with its clinical response rates, though risankizumab's even larger epitope (2,400 Ų) correlates with somewhat higher PASI-90 responses in that structural analysis.

These results are from an initial search, so the structural binding literature (particularly published crystallographic data for guselkumab itself, rather than hydrogen-deuterium exchange mapping) may be richer than what surfaced here.